Imugen, a division of Oxford Immunotec, Inc., is a clinical laboratory located in Norwood, MA. The staff collectively has decades of experience in the development and performance of specialized testing of clinical specimens for tick-borne diseases.
Failure to diagnose Lyme disease early increases the risk of long term complications including neurologic and arthritic manifestations. Misdiagnosis may result in inappropriate treatment and failure to appropriately treat the true cause of clinical symptoms simulating Lyme disease.
There is a demonstrable need for improved early diagnosis and improved diagnostic accuracy in endemic areas. Working closely with leading clinical researchers, Imugen developed assays for the laboratory detection of the Borrelia burgdorferi infection (the causative agent of Lyme disease). Imugen studied these assays in blinded studies of paired specimens, in correlation studies with clinical symptoms, and with retrospective studies on defined populations. Imugen has extensive clinical experience with over half a million tests performed.
Part of the difference of Imugen’s Lyme testing comes from the specific laboratory techniques used by its technical staff. The accuracy of the antibody capture method is coupled with reagents and materials which are internally produced. Imugen’s detailed understanding of the different behaviors of IgM, IgG, and IgA, at the various stages of infection, allows it to discriminate these stages. This experience is summarized in detailed interpretive comments supplied with each patient report.
Lyme disease is complex and often cannot be diagnosed solely on clinical indications. Laboratory testing must be of the highest accuracy since the clinical symptoms are generally not specific. Treatment is most effective in the early stages prior to dissemination of the infection, paradoxically the time period during which the commonly employed ELISA test is least sensitive. Thus Imugen’s testing becomes the method of choice for many clinicians in highly endemic areas for Lyme disease (i.e. Southeastern Massachusetts, Cape Cod, The Islands, New York and Long Island, Connecticut, Rhode Island, New Jersey and Pennsylvania).
Imugen has pioneered testing for other vector-borne diseases including state of the art testing for Babesiosis and Ehrlichiosis, as well as, HIV genotyping and drug resistance evaluations.
Imugen has offered clinical laboratory testing services for over 25 years and specializes in testing for tick-borne infections. Imugen is College of American Pathologists (CAP) accredited, Clinical Laboratory Improvement Amendments (CLIA) certified and is licensed as required by state regulations.
Imugen’s goal is to provide testing that truly services the needs of the clinicians without encouraging over utilization of tick-borne disease testing.